Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23013209 | 0.85 | HTT (0.44) | HTTALDH1A1NAMPTPOLBRXFP1 | |
| SCHEMBL7822502 | 0.83 | TP53 (0.47) | ALDH1A1MAPT | |
| SCHEMBL1907012 | 0.81 | DDAH1 (0.47) | — | |
| SCHEMBL7393 | 0.77 | CA1 (0.57) | ALDH1A1NAMPTCA1CA2TDP1 | |
| SCHEMBL29229109 | 0.77 | HTT (0.55) | HTTALDH1A1CA1CA2TDP1 | |
| Charcoal, Activated SCHEMBL31430427 | 0.76 | CA1 (0.55) | ALDH1A1NAMPTCA1CA2TDP1 | |
| SCHEMBL2240089 | 0.74 | HTT (0.63) | HTTALDH1A1CA1CA2TDP1 | |
| SCHEMBL7006276 | 0.74 | ALDH1A1 (0.50) | ALDH1A1MAPT | |
| SCHEMBL20764570 | 0.73 | PTPN11 (0.59) | ALDH1A1NAMPTCA1CA2TDP1 | |
| SCHEMBL7401479 | 0.73 | CA1 (0.53) | NAMPTCA1CA2TDP1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1932833-B1 | NITROGENATED HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KISSEI PHARMACEUTICAL (JP) | 2012-08-01 | — | — | EP | disclosed |
| US-7947707-B2 | Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-05-24 | — | — | US | disclosed |
| US-20090306396-A1 | NITROGENATED HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-1932833-A1 | NITROGENATED HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Kissei Pharmaceutical Co., Ltd. (JP) | 2008-06-18 | — | — | EP | disclosed |
| US-5215994-A | Treating or preventing hypertension or heart failure | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306396-A1 | NITROGENATED HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | XDH, CBR3, CBR1 | HTT 2813/4885ALDH1A1 280/4885NAMPT 1045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.